TP53 mutations in endometrial cancer contribute to clinically-relevant radiation resistance and highlight the potential for biomarker-driven radiosensitization strategies

Author:

Vargas RobertoORCID,Petty Aaron,Durmaz Arda,Lin-Rahardja Kristi,Reizes OferORCID,Debernardo Robert,Scott JacobORCID

Abstract

AbstractEndometrial cancer (EC) is the most common type of gynecologic malignancy in the United States, with over 65,950 new cases expected in 2022. Approximately 80% of cancer-related mortalities can be attributed to high-grade EC. Despite our ability to identify different biologic clusters of EC, we have yet to understand the functional and therapeutic impact of the key genomic alterations associated with poor prognosis EC and exploit this knowledge for therapeutic benefit. Given this, we set out to determine if and how common TP53 alterations found in high-grade ECs impact radiotherapy response, and if manipulation of this signaling pathway could be utilized for therapeutic intervention. Our work demonstrates that p53 signaling plays a significant role in radiotherapy response for EC and that leveraging this genomic data may allow us to exploit this pathway as a viable therapeutic target.

Publisher

Cold Spring Harbor Laboratory

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3